Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 28, Issue 3, Pages 489-492Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfs566
Keywords
FSGS; imatinib; RPGN
Categories
Ask authors/readers for more resources
Iyoda et al. have provided strong experimental evidence for beneficial effects of PDGF signalling inhibition in two seemingly unrelated glomerular diseases: rapidly progressive glomerulonephritis (RPGN) in the present study and focal and segmental glomerulosclerosis (FSGS) in a previous study. Novel insights into the pathogenesis of these two diseases have unravelled a common cellular mechanism: activation of parietal epithelial cells (PECs). In addition, recent studies have shown that PDGF signalling is sufficient to mediate the PEC activation and formation of cellular crescents, the hallmark of RPGN. In this comment, we make an attempt to assemble the pieces of the puzzle arguing that the activated PECs might play a significant role and could represent a target for novel treatment strategies for RPGN and FSGS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available